Nephrogenic diabetes insipidus (NDI) is a rare disorder that occurs when the kidneys are unable to concentrate urine. In most people, the body balances the fluids you drink with the amount of urine ...
Nephrogenic diabetes insipidus is a rare condition that results in excessive urination and thirst. It occurs when the kidneys no longer respond to the hormone arginine vasopressin (AVP). Symptoms ...
The most common cause of acquired nephrogenic diabetes insipidus is long-term lithium treatment. The management of lithium-induced nephrogenic diabetes insipidus is challenging, even when the drug is ...
Mechanistically, thirst starts with the excitation of osmoregulatory cells in a brain structure called the lamina terminalis, which is located in the anterior wall of the third ventricle. The lamina ...
Nephrogenic diabetes insipidus (NDI) is caused by inability of the kidneys to concentrate urine by reabsorbing water in the collecting duct NDI can be inherited (X-linked or autosomal) or acquired, ...
An increased or decreased ratio of apelin to copeptin reflects a disturbed osmotic and body fluid homeostasis in patients with central or nephrogenic diabetes insipidus, study data show. However, a ...
Taking lithium, which often treats bipolar disorder, can sometimes cause nephrogenic diabetes insipidus (NDI). However, stopping lithium can reverse NDI. Share on Pinterest AndreyPopov/Getty Images If ...
Aquaporin-2 (AQP2) is a critical water channel in the renal collecting ducts that governs water reabsorption and urine concentration. Dysregulation of AQP2, through genetic mutations or acquired ...
Diabetes insipidus is a rare condition that affects the body’s ability to balance fluid levels properly. The condition can lead to excess urine production and low urine osmolality, which refers to the ...
Diabetes insipidus (DI) is a rare disorder that differs greatly from the familiar type 2 and type 1 diabetes. DI happens when your body lacks enough hormones to signal to your kidneys to hang on to ...
Agonist-dependent desensitization and internalization of G protein-coupled receptors (GPCR) are mediated by the binding of arrestins to phosphorylated receptors. The affinity of arrestins for the ...
PHILADELPHIA--(BUSINESS WIRE)--NephroDI Therapeutics, Inc., a biopharmaceutical company developing NDI-5033 for the X-linked/congenital form of Nephrogenic Diabetes Insipidus (NDI), today announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback